Fiche du document
30 octobre 2019
- doi: 10.3390/ijms20215399
- issn: 1422-0067
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms20215399
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/31671550
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1422-0067
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D6D6341944604
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
TherapyCiter ce document
V. Cristina et al., « Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. », Serveur académique Lausannois, ID : 10.3390/ijms20215399
Métriques
Partage / Export
Résumé
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. Furthermore, checkpoint inhibitors are better tolerated than chemotherapy. The state of the art in the treatment of R/M HNSCC is changing, thanks to improved results for checkpoint inhibitors. Results for these treatments are also awaited in curative settings and for locally advanced HNSCC. Unfortunately, the response rate of immunotherapy is low. Therefore, the identification of predictive biomarkers of response and resistance to anti-PD1/PD-L1 is a key point for better selecting patients that would benefit the most from immunotherapy. Furthermore, the combination of checkpoint inhibitors with various agents is being currently evaluated to improve the response rate, prolong response duration, and even increase the chances for a cure. In this review, we summarize the most important results regarding immune targeting agents for HNSCC, predictive biomarkers for resistance to immune therapies, and future perspectives.